Digital PCR Patents: Top Companies & Filing Trends 2026
- 45.7% concentration. The five leading assignees account for 199 of the 435 records in scope, so freedom-to-operate work should start with their portfolios, not a broad landscape search.
- Filing has plateaued. Activity peaked at 52 records in 2023 and has since eased toward 8 in 2026 (a partial year), suggesting the core claim space is largely staked out.
- One subclass dominates. 95.4% of the 435 records carry a C12Q classification, while apparatus-side classes like B01L (15.4%) and bioinformatics-tagged G16B (8.0%) remain comparatively open.
What the digital PCR patent record shows
Digital PCR partitions a sample into thousands of independent reactions and counts positive versus negative partitions to reach an absolute molecular count, without relying on a standard curve. The 435 records captured here span filings tagged for partition count, dynamic range, rare allele detection, multiplexing and copy number variation claims, filtered to the core measurement and lab-apparatus classes (C12Q1, B01L3, B01L7). Most activity sits in the assay chemistry and detection layer rather than in fluidics hardware alone.
Filing runs from 2015 through the mid-2026 data cut-off, with the United States as the largest receiving office ahead of the EPO, WIPO's PCT route, China and Canada. Because publication lags filing by roughly 18 months, the most recent year of the trend understates real activity and should be read as a floor, not a ceiling.
Filing trend and technology composition
Two views of the same 435-record dataset: activity over time, and how records distribute across IPC subclasses. Since a single record can carry several IPC codes, the composition shares add up to more than 100%.
Filings rose to a 2023 peak, then eased
Annual counts climbed from 11 in 2017 toward a peak of 52 in 2023, sat at 32 by the 2022 midpoint, and have since declined toward 8 in 2026 — a partial year given the publication lag. Read the plateau as claim space filling up in the core chemistry, not as declining interest in the underlying technique.
C12Q dominates; apparatus and bioinformatics classes trail
C12Q (enzyme/DNA measuring and testing) appears on 95.4% of the 435 records, confirming this is overwhelmingly an assay-chemistry field. B01L (lab apparatus, 15.4%), C40B (combinatorial libraries, 8.3%) and G16B (bioinformatics, 8.0%) are present but far less saturated, which is where apparatus and data-analysis claims have more room to be distinctive.
Shares are the percentage of the 435 records in scope. A patent can carry several IPC classes, so the shares add up to more than 100%.
Go deeper on Digital PCR Technology with Eureka
This page is one run against one query. Ask Eureka your own question about digital pcr technology and every answer comes back with the patent numbers behind it.
Try EurekaThe most-cited foundational filings
Droplet digital PCR chip (US20200001301A1)
The filing discloses a droplet digital PCR chip built from bonded top and bottom pieces forming an inlet chamber, droplet storage chamber and injection hole, with droplet-generating channels sized shorter than the storage chamber so injected fluid emulsifies into discrete droplets as it moves from inlet to storage.Assignee and filing date are rendered separately above.
| # | Publication no. | Patent title | Citations |
|---|---|---|---|
| 1 | WO2012149042A2 | Methods and compositions for nucleic acid analysis | 411 |
| 2 | US20100069250A1 | Digital PCR Calibration for High Throughput Sequencing | 380 |
| 3 | US20110244455A1 | Digital analyte analysis | 291 |
| 4 | US20110250597A1 | Digital analyte analysis | 255 |
| 5 | US9347059B2 | Methods and compositions for nucleic acid analysis | 211 |
| 6 | US20110151442A1 | Direct Molecular Diagnosis of Fetal Aneuploidy | 203 |
| 7 | US20160201125A1 | Compositions and methods for molecular labeling | 202 |
| 8 | US8535889B2 | Digital analyte analysis | 179 |
| 9 | US20100304978A1 | Methods and compositions for identifying a fetal cell | 178 |
| 10 | US20150011430A1 | Methods and compositions for nucleic acid analysis | 141 |
Citation counts reflect influence within the searched corpus and skew toward older filings; treat them as a signal of foundational importance rather than current activity.
Each row carries its publication number; clicking a row searches Eureka by that number.
Put your own technology through the same analysis
Eureka on the web
When you want the answer in the next five minutes.
The agent works the prompt against patents and technical literature, citing every source.
Run your analysis now →MCP server & REST API
When it has to run inside your own pipeline.
Patent search, landscape analysis and assignee resolution as MCP tools. Drop them into any agent framework, or call REST directly.
Browse MCP servers →What the concentration and trend data mean for strategy
The ranking and trend line point to a field where core chemistry claims are largely settled among a small group, while apparatus and analysis-layer claims still have open ground.
The field is top-heavy, not fragmented
Five assignees account for 199 of the 435 records in scope, and the top ten extend that to 58.4%. A long tail of single- or few-filing entrants fills the remainder, which is typical of a technology where the founding chemistry patents have already been litigated and licensed.
Activity has cooled since the 2023 peak
Annual filings rose from 11 in 2017 to a peak of 52 in 2023, then declined toward 8 by 2026. Because publication lags filing by about 18 months, the 2026 figure is a partial-year floor, but the downward slope from 2023 through 2022's midpoint of 32 is a real signal of a maturing core.
Assay chemistry, not hardware, is the crowded layer
C12Q classification appears on 415 of 435 records, dwarfing B01L lab-apparatus coverage at 15.4% and bioinformatics-tagged G16B at 8.0%. New entrants competing purely on chemistry face the densest prior art; those building apparatus or data-analysis differentiation face comparatively less-claimed ground.
Eureka can read the same corpus for gaps instead of for coverage: under-claimed branches adjacent to digital pcr technology, with the prior art for and against each one.
Who holds the core claims, and where the gate sits
A small number of assignees built the founding portfolio; recent-year momentum shows most of that group filing less, not more, which is where the openings sit.
One assignee sets the pace by a wide margin
The leading assignee holds 127 records against 12 at fifth place and 10 at tenth, a steep drop-off that marks this as a leader-plus-long-tail structure rather than an evenly split field.
Even the incumbents are filing less
Recent-year momentum data shows established filers pulling back sharply year-on-year, with some leading names at zero filings in the latest year. That pattern is consistent with a core claim set that is already staked out rather than one still being actively contested.
Collaboration is limited and concentrated
Only ten co-assignee pairs appear across the dataset, and the strongest of them links related corporate entities within the same group rather than independent partners, indicating most digital PCR patenting happens solo rather than through joint filing.
| Assignee | Recent year | YoY |
|---|---|---|
| Bio-Rad Laboratories, Inc. | 3 | -50% |
| Sniper (Suzhou) Life Technology Co., Ltd. | 1 | — |
| TargetingOne Technology (Beijing) Corp. | 1 | — |
| RainDance Technologies, Inc. | 0 | — |
| Life Technologies Corp. | 0 | -100% |
| F. Hoffmann-La Roche & Co. AG | 0 | — |
| Countable Labs, Inc. | 0 | — |
| Countable Labs, Inc. | 0 | — |
Where to take this analysis
The dataset points to specific next steps depending on whether the goal is freedom-to-operate, R&D targeting, or portfolio benchmarking.
Run freedom-to-operate on the top filers
With 45.7% of records held by five assignees, targeted FTO review of those portfolios covers nearly half the field before touching the long tail.
Explore assignee portfolios in EurekaTrack the apparatus and bioinformatics classes
B01L, C40B and G16B carry far lower record shares than C12Q, and recent-year momentum among core chemistry leaders is declining — both point toward where new claims are more likely to clear.
Monitor emerging filings in EurekaCommon questions about digital PCR patents
The dataset's leading assignee holds 127 of the 435 records in scope, well ahead of the fifth-ranked filer at 12 and tenth-ranked at 10. That gap indicates a leader-plus-long-tail structure rather than a field split evenly among several large players. Anyone doing freedom-to-operate work should review the leader's portfolio first, since it alone represents a large share of the founding claims, before moving down the ranked list.
No, filing activity peaked at 52 records in 2023 and has since declined toward 8 in the most recent year, though that final year is partial and understated because publication lags filing by roughly 18 months. The slowdown from the 2022 midpoint of 32 records suggests the core assay-chemistry claims are largely staked out. This does not mean the underlying technology is stagnant, only that the most obvious chemistry claims have already been filed by the incumbents.
The dominant class is C12Q, covering enzyme and DNA measuring and testing, which appears on 95.4% of the 435 records in scope. Supporting classes include C12N for microorganisms and genetic engineering (18.6%), G01N for material analysis (17.0%), and B01L for lab apparatus (15.4%). Because a single record can carry multiple IPC codes, these shares add up to more than 100%, and they show the field is overwhelmingly assay-chemistry-driven rather than hardware-driven.
The lighter-claimed branches sit outside the saturated C12Q chemistry core, in areas like bioinformatics pipelines for partition-count calling (G16B at 8.0% of records), combinatorial-library-compatible chip formats (C40B at 8.3%), and bioreactor-integrated apparatus (C12M at 5.7%). These lower shares relative to C12Q's 95.4% indicate comparatively less-occupied claim space, though lighter filing density signals opportunity rather than a guarantee of allowability. A first claim there should target the apparatus or data-analysis layer rather than repeating chemistry already covered by the leading portfolios.
It is fairly concentrated: the top five assignees hold 199 of the 435 records in scope, or 45.7%, and the top ten extend that to 254 records, or 58.4%. The remainder is spread across a long tail of the other ranked assignees, many with only a handful of filings each. That combination of a dominant leader, a mid-tier group, and a large tail is typical of a technology where the foundational chemistry patents were filed early and litigated, leaving later entrants to compete on apparatus or application-specific claims.
Research Digital PCR Technology in depth with Eureka
Go past this page: query the whole digital pcr technology corpus yourself, in your own scope.
Every answer comes back with patent numbers you can open.
Disclaimer. This page is generated from Patsnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.
Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. Patsnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.
Machine translation. Assignee and organisation names originally recorded in Chinese, Japanese or Korean have been rendered into English by an AI translation step so that the tables stay readable. These renderings are best-effort and may not match a company’s registered English name; the original name is what the underlying patent record carries, and it is what any Eureka query launched from this page uses.